Allogeneic cytotoxic T lymphocytes that are derived from peripheral blood mononuclear cells (PBMCs) from healthy Epstein-Barr virus (EBV) seropositive donors and have been transduced with a viral vector expressing latent membrane protein 1 (LMP1), LMP2, and EBV nuclear antigen 1 (EBNA1). PBMCs are thawed and a portion of these cells are incubated with a replication-deficient adenovirus encoding a transgene that expresses an EBV polyepitope protein to produce antigen-presenting cells (APCs). These APCs are irradiated to arrest their replication and then added to the remaining PBMCs to stimulate and induce the expansion of EBV-specific T-cells that can target EBV transformed B lymphocytes

Competitive context

37 Active assets in the Secondary Progressive Multiple Sclerosis cohort.

View all 50 →

Same molecule, other indications

Allogeneic cytotoxic T lymphocytes that are derived from peripheral blood mononuclear cells (PBMCs) from healthy Epstein-Barr virus (EBV) seropositive donors and have been transduced with a viral vector expressing latent membrane protein 1 (LMP1), LMP2, and EBV nuclear antigen 1 (EBNA1). PBMCs are thawed and a portion of these cells are incubated with a replication-deficient adenovirus encoding a transgene that expresses an EBV polyepitope protein to produce antigen-presenting cells (APCs). These APCs are irradiated to arrest their replication and then added to the remaining PBMCs to stimulate and induce the expansion of EBV-specific T-cells that can target EBV transformed B lymphocytes is also rated in: